| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chemical that dissolves many substances that can affect the body. It is used for bladder inflammation, limb pain, and IV leakage, but it can also cause side effects and interact with other drugs. Dimethyl sulfoxide — DMSO is a small, highly polar organosulfur compound with the formula (CH3)2SO. It is formally classified as a polar aprotic solvent, membrane-permeability enhancer, cryoprotectant and pharmaceutical excipient; concentrated DMSO also has direct biological activity. Standard abbreviations are DMSO and Me2SO. Commercial DMSO is produced by oxidation of dimethyl sulfide, historically obtained as a kraft-pulping by-product. In cancer research, DMSO is primarily a solvent and experimental differentiation agent rather than a clinically established anticancer drug. Its biological effects are strongly concentration-, exposure-time-, cell-type- and formulation-dependent. Primary mechanisms (ranked):
Bioavailability / PK relevance: DMSO is rapidly absorbed across skin and biological membranes and distributes widely into tissues and body fluids. It is metabolized primarily to dimethyl sulfone and dimethyl sulfide; metabolites are eliminated through urine, feces, breath and skin. Systemic exposure can produce a characteristic garlic-like taste and odour. DMSO also increases tissue penetration of other chemicals, so pharmaceutical purity and control of contaminants are critical. In-vitro vs systemic exposure relevance: Most cancer differentiation, growth-arrest and cytotoxicity studies use approximately 0.5–2.5% DMSO, equivalent to roughly 70–350 mM. These sustained concentrations are generally not representative of safe systemic anticancer exposure. DMSO concentrations routinely treated as an inert vehicle can themselves alter membranes, transcription, metabolism, proliferation and drug responses; solvent controls must therefore use the lowest feasible concentration, commonly at or below 0.1%, with cell-specific validation. Clinical evidence status: Cancer evidence is predominantly preclinical and includes older leukemia-differentiation models and diverse cell-culture observations. DMSO has no established role as systemic or topical anticancer monotherapy and is not supported by anticancer RCT evidence. Its clinically recognized roles are intravesical symptomatic treatment of interstitial cystitis, cryopreservation of cells and tissues, and use as a penetration-enhancing pharmaceutical excipient. In oncology it is more relevant as a solvent, delivery vehicle, cryoprotectant and potential modifier of treatment response than as an active anticancer therapy. Mechanistic effects of dimethyl sulfoxide
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| In all eukaryotic cells, intracellular Ca2+ levels are maintained at low resting concentrations (approximately 100 nM) by the activity of the major Ca2+ extrusion system, the plasma membrane Ca2+-ATPase (PMCA), which exchanges extracellular protons (H+) for cytosolic Ca2+. Indeed, sustained elevation of [Ca2+]C in the form of overload, saturating all Ca2+-dependent effectors, prolonged decrease in [Ca2+]ER, causing ER stress response, and high [Ca2+]M, inducing mitochondrial permeability transition (MPT), are considered to be pro-death factors. In cancer the Ca2+-handling toolkit undergoes profound remodelling (figure 1) to favour activation of Ca2+-dependent transcription factors, such as the nuclear factor of activated T cells (NFAT), c-Myc, c-Jun, c-Fos that promote hypertrophic growth via induction of the expression of the G1 and G1/S phase transition cyclins (D and E) and associated cyclin-dependent kinases (CDK4 and CDK2). Thus, cancer cells may evade apoptosis through decreasing calcium influx into the cytoplasm. This can be achieved by either downregulation of the expression of plasma membrane Ca2+-permeable ion channels or by reducing the effectiveness of the signalling pathways that activate these channels. Such protective measures would largely diminish the possibility of Ca2+ overload in response to pro-apoptotic stimuli, thereby impairing the effectiveness of mitochondrial and cytoplasmic apoptotic pathways. Voltage-Gated Calcium Channels (VGCCs): Overexpression of VGCCs has been associated with increased tumor growth and metastasis in various cancers, including breast and prostate cancer. Store-Operated Calcium Entry (SOCE): SOCE mechanisms, such as STIM1 and ORAI1, are often upregulated in cancer cells, contributing to enhanced cell survival and proliferation. High intracellular calcium levels are associated with increased cell proliferation and migration, leading to a poorer prognosis. Calcium signaling can also influence hormone receptor status, affecting treatment responses. Increased Ca²⁺ signaling is associated with advanced disease and metastasis. Patients with higher CaSR expression may have a worse prognosis due to enhanced tumor growth and resistance to apoptosis. -Ca2+ is an important regulator of the electric charge distribution of bio-membranes. |
| 6724- | DMSO, | Ion transport through dimethyl sulfoxide (DMSO) induced transient water pores in cell membranes |
| - | in-vitro, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:72 Target#:38 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid